Patents by Inventor Shimon Sakaguchi

Shimon Sakaguchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating cancer with an anti-CCR8 that binds tumor infiltrating cells
    Patent number: 11932696
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: March 19, 2024
    Assignees: SHIONOGI & CO., LTD., OSAKA UNIVERSITY
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • ANTI-CTLA-4 ANTIBODY AND USE THEREOF
    Publication number: 20240002510
    Abstract: The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.
    Type: Application
    Filed: June 24, 2022
    Publication date: January 4, 2024
    Inventors: Hitoshi KATADA, Kanako TATSUMI, Yutaka MATSUDA, Shun SHIMIZU, Masaki KAMIMURA, Yasunori KOMORI, Yuji HORI, Tomoyuki IGAWA, Hiroki KAWAUCHI, Hiroki HAYASHI, Hiroaki SUSUMU, Shimon SAKAGUCHI
  • Compound, And Method For Producing Regulatory T Cells
    Publication number: 20230111840
    Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
    Type: Application
    Filed: December 7, 2022
    Publication date: April 13, 2023
    Applicants: Kyoto University, Astellas Pharma Inc.
    Inventors: Shimon SAKAGUCHI, Naganari OHKURA, Norihisa MIKAMI, Shuh NARUMIYA, Masahiko AKAMATSU, Guliang XIA, Hironori HARADA, Naoto NAKAMURA, Satoru UJIHARA, Hisao HAMAGUCHI
  • Compound, and method for producing regulatory T cells
    Patent number: 11578067
    Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 14, 2023
    Assignees: KYOTO UNIVERSITY, ASTELLAS PHARMA INC.
    Inventors: Shimon Sakaguchi, Naganari Ohkura, Norihisa Mikami, Shuh Narumiya, Masahiko Akamatsu, Guliang Xia, Hironori Harada, Naoto Nakamura, Satoru Ujihara, Hisao Hamaguchi
  • ANTI-CTLA-4 ANTIBODY AND USE THEREOF
    Publication number: 20230020377
    Abstract: The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.
    Type: Application
    Filed: June 24, 2022
    Publication date: January 19, 2023
    Inventors: Hitoshi KATADA, Kanako Tatsumi, Yutaka Matsuda, Shun Shimizu, Masaki Kamimura, Yasunori Komori, Yuji Hori, Tomoyuki Igawa, Hiroki Kawauchi, Hiroki Hayashi, Hiroaki Susumu, Shimon Sakaguchi
  • T cell-redirected antigen-binding molecule for cells having immunosuppression function
    Patent number: 11505605
    Abstract: It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a T cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking T cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: November 22, 2022
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Osaka University
    Inventors: Tomoyuki Igawa, Takahiro Ishiguro, Shimon Sakaguchi, Hiroyoshi Nishikawa
  • Novel Anti-CCR8 Antibody
    Publication number: 20220064312
    Abstract: Disclosed is a novel anti-CCR8 antibody. The antibody can be used for treating or preventing cancers or the like.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 3, 2022
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Mai Yoshikawa, Tatsuya Takahashi, Junji Onoda, Sunao Imai, Etsuo Nakamura, Kentaro Furukawa, Tsuguo Miyauchi, Tetsuya Yoshida, Morio Nagira, Naganari Ohkura, Atsushi Tanaka, Shimon Sakaguchi, Hisashi Wada, Atsunari Kawashima
  • Method for Generating Regulatory T Cells
    Publication number: 20210238551
    Abstract: Provided is a method for producing regulatory T cells, comprising the step of culturing mammalian-derived peripheral T cells in a medium comprising TGF? and IL-2 in the presence of CD3 stimulation and in the absence of CD28 stimulation. The medium may further comprise ascorbic acid. The method may further comprise the step of culturing the obtained cell culture in a medium comprising IL-2.
    Type: Application
    Filed: August 21, 2019
    Publication date: August 5, 2021
    Applicant: Osaka University
    Inventors: Shimon Sakaguchi, Norihisa Mikami
  • Pharmaceutical Composition for Cancer Treatment
    Publication number: 20210115148
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Application
    Filed: December 28, 2020
    Publication date: April 22, 2021
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Pharmaceutical Composition for Cancer Treatment
    Publication number: 20210047421
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Application
    Filed: October 30, 2020
    Publication date: February 18, 2021
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Immunopotentiator potentiating tumor immunity or infection immunity
    Patent number: 10842790
    Abstract: An object of the present invention is to provide an immunopotentiating agent for reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity. Imatinib and/or a salt thereof has the action of reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity, and can be used as an active ingredient for the immunopotentiating agent.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: November 24, 2020
    Assignee: OSAKA UNIVERSITY
    Inventors: Hiroyoshi Nishikawa, Shimon Sakaguchi, Atsushi Tanaka
  • METHOD FOR PREPARING ANTIGEN-SPECIFIC REGULATORY T CELLS
    Publication number: 20200299645
    Abstract: Provided is a method for producing regulatory T cells for inducing immune tolerance in a subject. The method comprises the step of co-culturing regulatory T cells obtained from the subject with dendritic cells derived from iPS cells.
    Type: Application
    Filed: December 27, 2017
    Publication date: September 24, 2020
    Inventors: Hiroshi KAWAMOTO, Shimon SAKAGUCHI, Kyoko MASUDA, Keiji HIROTA, Junji UEHORI
  • Pharmaceutical Composition for Cancer Treatment
    Publication number: 20200232973
    Abstract: The disclosure provides a method of measuring an efficacy of a drug composition for cancer and a method for treating a cancer by administering to a subject an effective amount of a pharmaceutical composition having a polypeptide that binds to a peptide produced by cDNA of GenBank ACC No. NM_005201.3 or NM_007720.2.
    Type: Application
    Filed: January 2, 2020
    Publication date: July 23, 2020
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Pharmaceutical Composition for Cancer Treatment
    Publication number: 20200222463
    Abstract: The disclosure provides a pharmaceutical composition with a polypeptide that binds to a peptide produced by cDNA of GenBank ACC No. NM_005201.3 or NM_007720.2, and methods of use thereof.
    Type: Application
    Filed: January 2, 2020
    Publication date: July 16, 2020
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • METHOD FOR INDUCING REGULATORY T CELL
    Publication number: 20200095549
    Abstract: Provided is a method for inducing regulatory T cells, comprising a step of inhibiting the expression of Satb1 or the function of Satb1 in peripheral conventional T cells.
    Type: Application
    Filed: December 19, 2017
    Publication date: March 26, 2020
    Inventors: Shimon SAKAGUCHI, Yohko KITAGAWA, Norihisa MIKAMI
  • Method of treating cancer with an anti-CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8
    Patent number: 10550191
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: February 4, 2020
    Assignees: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Novel Compound, And Method For Producing Regulatory T Cells
    Publication number: 20190382403
    Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
    Type: Application
    Filed: January 30, 2018
    Publication date: December 19, 2019
    Applicants: Kyoto University, Astellas Pharma Inc.
    Inventors: Shimon SAKAGUCHI, Naganari OHKURA, Norihisa MIKAMI, Shuh NARUMIYA, Masahiko AKAMATSU, Guliang XIA, Hironori HARADA, Naoto NAKAMURA, Satoru UJIHARA, Hisao HAMAGUCHI
  • Method for forming an immune-tolerant site and method for attracting immunosuppressive cells
    Patent number: 10238714
    Abstract: A method for forming an immune-tolerant site, and a method for attracting immunosuppressive cells, comprising contacting an agent comprising SEK-1005 (Ser, 3-hydroxy-N-[2-hydroxy-1-oxo-2-tetrahydro-2-hydroxy-6-methyl-5-(2-methylpropyl)-2H-pyran-2-yl-propyl]-Leu-Pip(hexahydro-3-pyridazinecarbonyl)-N-hydroxy-Ala-N-methyl-Phe-Pip-rho-lactone) and/or fibroblast growth factor (FGF) with a site in the body tissue.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: March 26, 2019
    Assignees: KYOTO UNIVERSITY, ARKRAY, Inc., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Hiroo Iwata, Rei Kuwabara, Masahide Hamaguchi, Kunio Hirano, Shimon Sakaguchi
  • PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
    Publication number: 20190071508
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Application
    Filed: November 7, 2018
    Publication date: March 7, 2019
    Applicants: SHIONOGI & CO., LTD., OSAKA UNIVERSITY
    Inventors: Tetsuya YOSHIDA, Yujiro KIDANI, Mitsunobu MATSUMOTO, Takayuki KANAZAWA, Satomi SHINONOME, Kanji HOJO, Naganari OHKURA, Shimon SAKAGUCHI, Atsushi TANAKA, Hisashi WADA, Atsunari KAWASHIMA, Norio NONOMURA
  • T Cell-Redirected Antigen-Binding Molecule For Cells Having Immunosuppression Function
    Publication number: 20170260271
    Abstract: It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a T cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking T cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions.
    Type: Application
    Filed: May 13, 2015
    Publication date: September 14, 2017
    Applicants: Chugai Seiyaku Kabushiki Kaisha, Osaka University
    Inventors: Tomoyuki IGAWA, Takahiro ISHIGURO, Shimon SAKAGUCHI, Hiroyoshi NISHIKAWA